STERIS PLC

Steris PLC tops Q1 2026 earnings, boosting revenue by 7.3% and guiding 2027 EPS to $11.10‑$11.30 while expanding capex to $450 m for new plant capacity.

STERIS PLC’s stock dipped slightly, reflecting wider medical‑device market trends, yet its €18.3 bn cap, diverse infection‑prevention products and global presence keep it poised for future growth.

STERIS plc has announced a quarterly dividend of $0.63 per share, to be paid on December 18, 2025, to shareholders of record as of November 18, 2025.

STERIS PLC reported strong financial results for Q1 2026, with earnings per share exceeding expectations, despite a slight dip in stock price following a leadership transition.

STERIS PLC, a leading health care equipment and supplies company, has shown a positive stock performance and growth potential, with a market capitalization of $23.95 billion and a “hold” rating from Jefferies.

STERIS PLC, a market leader in infection prevention, faces crucial challenges as it navigates a competitive healthcare sector, internal pressures, and the need to diversify its offerings.

Steris PLC reported strong fourth-quarter earnings, exceeding revenue expectations and driving a 4.73% increase in its stock price, solidifying its position as a top performer in the S&P 500.

STERIS PLC has demonstrated a strong financial performance over the past five years, with a 53.19% stock price increase, and is expected to report positive earnings in Q4 2025, with analysts forecasting a 3.50% sales increase to $1.47 billion.